Találati lista | Tudóstér

001-es BibID:	BIBFORM103357
035-os BibID:	(cikkazonosító)e27622 (WOS)000297555300037 (Scopus)81055129712
Első szerző:	Kissling, Esther
Cím:	I-MOVE Multi-Centre Case Control Study 2010-11 : overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe / Esther Kissling, Marta Valenciano, Jean Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Pawel Stefanoff, Baltazar Nunes, Daniela Pitigoi, Amparo Larrauri, Isabelle Daviaud, Judit Krisztina Horvath, Joan O'Donnell, Thomas Seyler, Iwona Anna Paradowska-Stankiewicz, Pedro Pechirra, Alina Elena Ivanciuc, Silvia Jiménez-Jorge, Camelia Savulescu, Bruno Christian Ciancio, Alain Moren
Dátum:	2011
ISSN:	1932-6203
Megjegyzések:	Background: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Methods: Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination. Results: We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ?60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B. Conclusions: Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Plos One. - 6 : 11 (2011), p. 1-11. -
További szerzők:	Valenciano, Marta Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Barret, Anne-Sophie Rizzo, Caterina Stefanoff, Pawel Nunes, Baltazar Pitigoi, Daniela Larrauri, Amparo Daviaud, Isabelle Horváth Judit Krisztina O'Donnell, Joan Seyler, Thomas Paradowska-Stankiewicz, Iwona Pechirra, Pedro Ivanciuc, Alina Elena Jiménez-Jorge, Silvia Savulescu, Camelia Ciancio, Bruno Moren, Alain
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103352
035-os BibID:	(Scopus)84873314436
Első szerző:	Kissling, Esther
Cím:	Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe : results from the I-MOVE multicentre case-control study / E. Kissling, M. Valenciano, A. Larrauri, B. Oroszi, J. M. Cohen, B. Nunes, D. Pitigoi, C. Rizzo, J. Rebolledo, I. Paradowska-Stankiewicz, S. Jiménez-Jorge, J. K. Horváth, I. Daviaud, R. Guiomar, G. Necula, A. Bella, J. O'Donnell, M. Głuchowska, B. C. Ciancio, A. Nicoll, A. Moren
Dátum:	2013
ISSN:	1560-7917
Megjegyzések:	Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case?control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Eurosurveillance. - 18 : 5 (2013), p. 1-10. -
További szerzők:	Valenciano, Marta Larrauri, Amparo Oroszi Beatrix (1970-) (orvos, epidemiológus) Cohen, Jean Marie Nunes, Baltazar Pitigoi, Daniela Rizzo, Caterina Rebolledo, J. Paradowska-Stankiewicz, Iwona Jiménez-Jorge, Silvia Horváth, J. K. Daviaud, Isabelle Guiomar, Raquel Necula, G. Bella, Antonino O'Donnell, Joan Głuchowska, M. Ciancio, Bruno Nicoll, A. Moren, Alain
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103355
035-os BibID:	(WOS)000355705700014 (Scopus)84929289547
Első szerző:	Valenciano, Marta
Cím:	The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2) / Marta Valenciano, Esther Kissling, Annicka Reuss, Silvia Jiménez-Jorge, Judit K. Horváth, Joan M. O. Donnell, Daniela Pitigoi, Ausenda Machado, Francisco Pozo, I-MOVE Multicentre Case Control Study Team
Dátum:	2015
ISSN:	0264-410X
Megjegyzések:	Background In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013?2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013?2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season. Methods Practitioners systematically selected ILI patients to swab within eight days of symptom onset. We compared cases (ILI positive to influenza A(H3N2) or A(H1N1)pdm09) to influenza negative patients. We calculated VE for the two influenza A subtypes and adjusted for potential confounders. We calculated heterogeneity between sites using the I2 index and Cochrane's Q test. If the I2 was <50%, we estimated pooled VE as (1 minus the OR) ? 100 using a one-stage model with study site as a fixed effect. If the I2 was >49% we used a two-stage random effects model. Results We included in the A(H1N1)pdm09 analysis 531 cases and 1712 controls and in the A(H3N2) analysis 623 cases and 1920 controls. For A(H1N1)pdm09, the Q test (p = 0.695) and the I2 index (0%) suggested no heterogeneity of adjusted VE between study sites. Using a one-stage model, the overall pooled adjusted VE against influenza A(H1N1)pdm2009 was 47.5% (95% CI: 16.4?67.0). For A(H3N2), the I2 was 51.5% (p = 0.067). Using a two-stage model for the pooled analysis, the adjusted VE against A(H3N2) was 29.7 (95% CI: ?34.4?63.2). Conclusions The results suggest a moderate 2013?2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Influenza vaccine Influenza vaccine effectiveness Multicentre study Test-negative design Vaccine effectiveness
Megjelenés:	Vaccine. - 33 : 24 (2015), p. 2813-2822. -
További szerzők:	Kissling, Esther Reuss, Annicka Jiménez-Jorge, Silvia Horváth Judit Krisztina Donnell, Joan M. O. Pitigoi, Daniela Machado, Ausenda Pozo, Francisco Oroszi Beatrix (1970-) (orvos, epidemiológus) I-MOVE Multicentre Case Control Study Team
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: